Jan 30, 2017

Show description/summary:1) Progressive rural-urban disparity in acute stroke care2) What's Trending: Upcoming changes regarding the Neurology® Resident & Fellow section 3) Topic of the Month: Neuromuscular topicsThis podcast begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the January 31, 2017 issue of Neurology. In the first segment, Dr. Andy Southerland talks with Dr. Allison Willis about her paper on disparities in stroke care between rural and urban areas. Dr. Ted Burns talks with Dr. Eric Olsen regarding CRISPR at the 2016 AANEM meeting for our “What's Trending” feature of the week. In the next part of the podcast, Dr. Ted Burns focuses his interview with Dr. Merit Cudkowicz on amyotrophic lateral sclerosis (ALS). Disclosures can be found at Neurology.org.DISCLOSURES: Dr. Southerland serves as Podcast Deputy Editor for Neurology; receives research support from the American Heart Association-American Stroke Association National Clinical Research Program, American Academy of Neurology, American Board of Psychiatry and Neurology, Health Resources Services Administration and the NIH; has a provisional patent application titled: “Method, system and computer readable medium for improving treatment times for rapid evaluation of acute stroke via mobile telemedicine;” and gave legal expert review. Dr. Allison Willis has served on the editorial board of Pharmacoepidemiology and Drug Safety; and has received research support from NIH/NINDS.Dr. Burns serves as Podcast Editor for Neurology®; and has received research support for consulting activities with UCB, CSL Behring, Walgreens and Alexion Pharmaceuticals, Inc. Dr. Eric Olson holds patents describing DMD gene editing.Dr. Merit Cudkowicz has served on the editorial board of DSMB AstraZenica (through Clintrex); has served on the editorial boards of Neurotherapeutics and JAMA Neurology; holds a patent for Metabolomics in ALS; receives publishing royalties from UpToDate; has been a consultant for Cytokinetics, Biogen-Idec, Voyager, Biohaven, Astrazenica, Genentech, Karyopharm, and Neuraltis; has received research support from NINDS, the Muscular Dystrophy Association, the ALS Association, and the ALS Finding a Cure Association; and has provided expert witness for defense (TEVA).All other participants have no disclosures.